{
    "clinical_study": {
        "@rank": "48561", 
        "arm_group": [
            {
                "arm_group_label": "Aleglitazar", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This multicenter, randomized, double-blind, placebo-controlled study will evaluate the\n      efficacy, safety and tolerability of aleglitazar monotherapy in patients with Type 2\n      diabetes mellitus who are drug-na\u00efve to anti-hyperglycemic therapy. Patients will be\n      randomized to receive either aleglitazar 150 mcg orally daily or placebo for 26 weeks."
        }, 
        "brief_title": "A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Na\u00efve to Anti-Hyperglycemic Therapy", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patient, >/= 18 years of age\n\n          -  Diagnosis of Type 2 diabetes mellitus within 12 months prior to screening\n\n          -  Drug-na\u00efve (defined as no anti-hyperglycemic medication for at least 12 weeks prior\n             to screening and for not longer than 3 consecutive months at any time in the past)\n\n          -  HbA1c >/= 7% and </= 9.5% at screening or within 4 weeks prior to screening and at\n             pre-randomization visit\n\n          -  Fasting plasma glucose </= 13.3 mmol/L (</= 240 mg/dL) at pre-randomization visit\n\n          -  Agreement to maintain diet and exercise habits implemented during the run-in phase\n             during the full course of the study\n\n        Exclusion Criteria:\n\n          -  Pregnant women, women intending to become pregnant during the study period, currently\n             lactating women, or women of child-bearing potential not using highly effective,\n             medically approved birth control methods\n\n          -  Diagnosis or history of:\n\n               1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or\n                  secondary forms of diabetes\n\n               2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma\n                  within the past 6 months\n\n          -  Any previous treatment with thiazolidinedione or with a dual PPAR agonist\n\n          -  Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12\n             weeks prior to screening with the exception of stable (>= 1 month) statin therapy\n\n          -  Prior intolerance to fibrate\n\n          -  Triglycerides (fasting) > 4.5 mmol/L (> 400 mg/dL) at screening or within 4 weeks\n             prior to screening\n\n          -  Clinically apparent liver disease\n\n          -  Anemia at or within 4 weeks prior to screening\n\n          -  Inadequate renal function\n\n          -  Symptomatic congestive heart failure NYHA Class II-IV at screening\n\n          -  Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke\n             within 6 months prior to screening visit\n\n          -  Known macular edema at screening or prior to screening visit\n\n          -  Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ\n             carcinoma of the cervix, or in situ prostate cancer) within the past 5 years\n\n          -  Uncontrolled hypertension\n\n          -  History of active substance abuse (including alcohol) within the past 2 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871428", 
            "org_study_id": "YC28037"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aleglitazar", 
                "description": "150 mcg orally daily", 
                "intervention_name": "aleglitazar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "matching aleglitazar placebo orally daily", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hypoglycemic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "400016"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200003"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shiyan", 
                        "country": "China", 
                        "zip": "442000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China", 
                        "zip": "215004"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alor Setar", 
                        "country": "Malaysia", 
                        "zip": "05400"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perak", 
                        "country": "Malaysia", 
                        "zip": "33400"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Hong Kong", 
                "Malaysia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS ITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NA\u00cfVE TO ANTI-HYPERGLYCEMIC THERAPY", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c", 
            "safety_issue": "No", 
            "time_frame": "from baseline to Week 26"
        }, 
        "removed_countries": {
            "country": [
                "Philippines", 
                "Taiwan"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871428"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in lipids", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 26"
            }, 
            {
                "measure": "Change in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 26"
            }, 
            {
                "measure": "Responder rates, defined as target HbA1c: < 7.0%, < 6.5% at Week 26", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change in homeostatic index of insulin sensitivity (by HOMA-IS)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 26"
            }, 
            {
                "measure": "Change in homeostatic index of beta cell function (by HOMA-BFC)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 26"
            }, 
            {
                "measure": "Change in markers of insulin sensitivity/cardiovascular risk", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 26"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 30 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}